secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-05-19T12:07:26+00:00
Accession:  0001193125-26-229714
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Artiva CFO departs; CEO assumes financial duties; Miralles becomes President
----------------------------------------------------------------------------

- CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
- CEO Fred Aslan becomes principal financial and accounting officer after stepping down as President.
- Diego Miralles resigns from board, appointed President and Head of R&D; $600k salary, 45% bonus target.
- Miralles awarded inducement equity: 232,500 options and 77,500 RSUs under 2025 Inducement Plan.
- Board size reduced from 8 to 7; Miralles's consulting agreement ended May 17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/artv-20260518.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer